The UK’s health regulator has issued a warning that a counterfeit batch of AstraZeneca’s prostate cancer treatment Casodex has been found in the supply chain, the third such case in a week. The UK’s ...

Recent results from the phase 2 TERRAIN trial showed Xtandi increased progression-free survival by nearly 10 months compared with Casodex in patients with metastatic castration-resistant prostate ...

To assess the recommended-effectiveness of bicalutamide Casodex as bye treatment in early prostate cancer Casodex drug price. The very horizon was 15 years and the active was conducted from the u ...

The ongoing Early Prostate Cancer (EPC) programme is investigating the effects of adding bicalutamide 150 mg/day to standard care (radiotherapy, radical prostatectomy or watchful waiting). This study ...

Dublin, Dec. 07, 2021 (GLOBE NEWSWIRE) -- The "Research Report on China's Bicalutamide Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering. Bicalutamide, originally developed ...

(RTTNews) - AstraZeneca (AZN, AZN.L) announced Friday that it has sold the commercial rights to Arimidex (anastrozole) and Casodex (bicalutamide) in a number of European, African and other countries ...

CASODEX 150 mg daily is not approved for use in patients with locally advanced (T3-4, NX, M0) cancer of the prostate. Following discontinuation of all M1 patients, the trials continued with the T3-4, ...

For several years AstraZeneca has been selling off rights to its older drugs to raise cash as it develops a new generation of drugs, and this pattern has continued as it sold its Arimidex and Casodex ...

Sharpe, from Maloney, the founder of Kafi Cakes and Stuff, is on the cusp of turning 29 in June, and already she has carved out a name for herself in Trinidad and To­bago’s growing home-based food ...

The Institute for Safe Medication Practices (ISMP) has reported medication errors due to name confusion between Kapidex (dexlansoprazole) and Casodex (bicalutamide). Kapidex is used to treat erosive ...

WASHINGTON, Dec. 8 (UPI) -- A new analysis of the Early Prostate Cancer trial may restore physician confidence in AstraZeneca's prostate cancer treatment Casodex, the analyst firm Datamonitor said in ...